<DOC>
	<DOCNO>NCT01189656</DOCNO>
	<brief_summary>To preliminarily evaluate efficiency safety therapeutic double- plasmid HBV DNA vaccine HBeAg-positive , chronic hepatitis B patient , provide evidence next dosing regimen .</brief_summary>
	<brief_title>A Clinical Study Therapeutic Double-plasmid Hepatitis B Virus ( HBV ) DNA Vaccine Patients With HBeAg-positive Chronic Hepatitis B</brief_title>
	<detailed_description>The current study multicenter , randomize , double-blind , placebo- control clinical trial . The eligible subject assign randomly 2 arm , Vaccine + Lamivudine group Placebo + Lamivudine group , respectively , ratio 2:1 . The efficacy variable include change HBV DNA load Week 72 , visit rate subject HBV DNA titer reduce &gt; 2 logarithm , change HBeAg HBsAg titer , change ALT , HBsAg/HBeAg serum conversion rate , INF-gamma expression level peripheral blood mononuclear cell ( PBMC ) , amount HBV-specific CTL , change expression level peripheral cytokine ( IL-4 , IL-10 , IL-12 INF-gamma ) baseline level .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>The following condition must meet enrolled subject : 1 . Aged 1865 year either sex ; 2 . HBV serology meet follow criterion : HBsAgpositive lasting least 6 month time screen ; HBeAgpositive time screening ; Serum HBV DNA≥1.0×10E5 copies/ml time screen 3 . 80U/L &lt; ALT &lt; 400U/L ; 4 . TBIL &lt; 40μmol/L ; 5 . No YMDD mutation HBV drug resistance gene 6 . Subjects agree participate clinical trial take antiHBV therapeutic study ; 7 . Subjects understand sign ICF approve EC , able comply study procedure complete study . Subjects meet follow condition enrol study : 1 . Was suspect HCC follow evidence : BUltrasound imaging show occupy lesion ; Continuingly elevate serum AFP level even BUltrasound normal ; AFP &gt; 100ng/ml ; 2 . With acute hepatic decompensation cause liver disease aggravation clinical symptom decompensated liver disease baseline ; 3 . Serum Cr≥1.5mg/dl ( ≥130μmol/l ) time screen ; 4 . Serum amylase &gt; twofold upper limit normal reference value ; 5 . Hb ( male &lt; 100g/ L , female &lt; 90g/L ) , WBC &lt; 3.5×10E9/L , PLT &lt; 60×10E9/L ( except hypersplenism cirrhosis ) ; 6 . Coinfection HCV ( antiHCV positive ) , HIV antiHAV IgM positive , antiHDV IgM positive , antiHEV IgM positive , antiCMV IgM positive autoimmune hepatitis ( e.g . antinuclear antibody titer &gt; 1:160 ) active liver disease cause know unknown factor ; 7 . Any serious disease active disease hepatitis B consider investigator potential factor may interfere therapy , assessment compliance protocol , include uncontrolled disease clinical significance , e.g . kidney , heart , lung , blood vessel , neurogenic , digestive system metabolic disease ( diabetes , hyperthyroidism , adrenal gland disease ) , autoimmune dysfunction , tumor , etc ; 8 . History alcohol drug abuse consider investigator could affect subject 's compliance protocol could influence result analysis ; 9 . Pregnant breastfeed female subject , plan pregnant course study male subject ' companion plan pregnant course study ; 10 . Having use immunosuppressive agent , immunomodulators ( thymosin ) , cytotoxic drug within 6 month transaminasedecreasing drug within one month prior initiation study ; 11 . Having use antiHBV drug ( Lamivudine , interferon , adefovir , entecavir , sebivo , etc . ) within 6 month prior initiation study ; 12 . Had plan liver transplantation ; 13 . Having receive experimental drug treatment study within 3 month prior screen ; 14 . Allergic nucleoside drug nucleoside analogue ; 15 . Not agree study protocol factor consider eligible study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Chronic hepatitis B patient</keyword>
</DOC>